Clinical Trials Logo
  1. Home
  2. Atopic Dermatitis
  3. NCT05904509
  4. Details
NCT05904509 Clinical Trial

Insulin Resistance in Atopic Dermatitis Patients

Atopic Dermatitis Clinical Trial

Official title:
The Relationship Between Insulin Resistance and Disease Severity and Duration in Atopic Dermatitis Patients

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05904509
Other study ID # E-54022451-050.05.04-56968
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 1, 2022
Est. completion date October 1, 2023

Study information
Verified date February 2024
Source Bezmialem Vakif University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the study is to determine the relationship between insulin resistance and disease duration and severity of atopic dermatitis.

Description:

The aim of the study is to determine the relationship between insulin resistance and disease duration and severity of atopic dermatitis. EASI and SCORAD values and disease duration of atopic dermatitis patients are calculated during the examination. HOMA-IR blood test result is compared with the results.

Recruitment information / eligibility
Status Completed
Enrollment 32
Est. completion date October 1, 2023
Est. primary completion date October 1, 2023
Accepts healthy volunteers No
Gender All
Age group 2 Years to 80 Years
Eligibility Inclusion Criteria: - Atopic dermatitis patients confirmed by a dermatologist Exclusion Criteria: - patients younger than 2 years - patients older than 80 years - Atopic dermatitis patients without HOMA-IR result

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Turkey Bezmialem Vakif University Hospital Istanbul

Sponsors (1)
Lead Sponsor Collaborator
Bezmialem Vakif University

Country where clinical trial is conducted

Turkey, 

Outcome
Type Measure Description Time frame Safety issue
Primary HOMA-IR Patients' blood test show the result of fasting insulin (microU/L) x fasting glucose (mmol/L)/22.5 12 months
Primary SCORAD index Severity scoring of atopic dermatitis is calculated for each patient in the study. 6 intensity items (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, dryness); 2 subjective symptoms(itch, sleeplessness); body surface area are studied. Max score is 103. 12 months
Primary EASI index Eczema Area and Severity Index is calculated for each patient in the study. Body surface area, 4 intensity items(erythema, induration, excoriation, lichenification) are studied. Max score is 72. 12 months
Primary Duration of the disease The time from the first onset of symptoms of the disease to the present. The relationship between insulin resistance and disease duration is examined 12 months
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2